The development of S100 neutralizing antibodies and small molecules is already a current therapeutic approach in cancer, autoimmune diseases and chronic inflammatory disorders, as reviewed in Bresnick (2018), and could present a promising strategy for AD as well. This evidence concerns the gene S100B and Alzheimer disease.